MARKET

OCUL

OCUL

Ocular
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.99
-0.52
-2.81%
After Hours: 17.99 0 0.00% 17:22 03/08 EST
OPEN
18.44
PREV CLOSE
18.51
HIGH
19.45
LOW
17.68
VOLUME
1.62M
TURNOVER
--
52 WEEK HIGH
24.30
52 WEEK LOW
3.775
MARKET CAP
1.35B
P/E (TTM)
-10.1455
1D
5D
1M
3M
1Y
5Y
The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings
Biotech stocks continued to move southward in the week ended March 5, as the broader market extended its sell-off. Though light on news, the week did witness earnings releases from smaller biopharma companies, coronavirus vaccine program updates, mixed FDA...
Benzinga · 2d ago
The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4)
Benzinga · 3d ago
Will Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should Know
Zacks.com · 3d ago
BRIEF-Ocular Therapeutix Announces FDA Acceptance Of Supplemental New Drug Application For Dextenza (Dexamethasone Ophthalmic Insert) For The Treatment Of Ocular Itching Associated With Allergic Conjunctivitis
reuters.com · 4d ago
Ocular surges on FDA review for label expansion for Dextenza
Ocular Therapeutix (OCUL) has risen ~4.3% in the post-market after announcing that the FDA has accepted its supplemental New Drug Application (sNDA) for Dextenza (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use.The PDUFA action
Seekingalpha · 4d ago
Ocular Therapeutix Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
Business Wire · 4d ago
Will Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should Know
Zacks · 4d ago
Raymond James Keeps Their Buy Rating on Ocular Therapeutix (OCUL)
Raymond James analyst Dane Leone maintained a Buy rating on Ocular Therapeutix (OCUL) yesterday. The company's shares closed last Wednesday at $17.57.
SmarterAnalyst · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OCUL. Analyze the recent business situations of Ocular through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OCUL stock price target is 25.50 with a high estimate of 30.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 194
Institutional Holdings: 53.24M
% Owned: 70.70%
Shares Outstanding: 75.30M
TypeInstitutionsShares
Increased
48
8.39M
New
64
7.67M
Decreased
35
5.50M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.16%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/Independent Director
Charles Warden
President/Chief Executive Officer/Director
Antony Mattessich
Chief Financial Officer
Donald Notman
Corporate Executive
Michael Goldstein
Chief Operating Officer
Patricia Kitchen
Senior Vice President
Rabia Ozden
Senior Vice President
Christopher White
Independent Director
Jeffrey Heier
Independent Director
Richard Lindstrom
Independent Director
Bruce Peacock
Independent Director
Suh Hong Seung
Independent Director
Leslie Williams
No Data
About OCUL
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.

Webull offers kinds of Ocular Therapeutix Inc stock information, including NASDAQ:OCUL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCUL stock methods without spending real money on the virtual paper trading platform.